Lys146
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys146  -  TR-beta1 (human)

Site Information
LHPsYSCkYEGKCVI   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 27490403

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 2 ) , immunoprecipitation ( 2 ) , modification-specific antibody ( 2 ) , mutation of modification site ( 1 , 2 ) , western blotting ( 2 )
Disease tissue studied:
liver cancer ( 2 )
Relevant cell line - cell type - tissue:
3T3 (fibroblast) ( 1 ) , adipocyte ( 1 ) , adipose tissue ( 2 ) , C2C12 (myoblast) ( 2 ) , GH3 (epithelial) ( 2 ) , heart ( 2 ) , HepG2 (hepatic) ( 2 ) , liver ( 2 )

Upstream Regulation
Treatments:
liothyronine ( 2 )

Downstream Regulation
Effects of modification on TR-beta1:
intracellular localization ( 2 ) , molecular association, regulation ( 1 , 2 )
Effects of modification on biological processes:
cell differentiation, induced ( 1 ) , cell growth, induced ( 1 ) , signaling pathway regulation ( 1 ) , transcription, altered ( 2 ) , transcription, induced ( 1 ) , transcription, inhibited ( 1 )
Induce interaction with:
DNA ( 2 ) , N-CoR1 (human) ( 2 )
Inhibit interaction with:
CBP (human) ( 2 ) , DNA ( 1 )

References 

1

Liu YY, et al. (2015) Thyroid hormone receptor sumoylation is required for preadipocyte differentiation and proliferation. J Biol Chem 290, 7402-15
25572392   Curated Info

2

Liu YY, et al. (2012) Thyroid hormone receptor isoform-specific modification by small ubiquitin-like modifier (SUMO) modulates thyroid hormone-dependent gene regulation. J Biol Chem 287, 36499-508
22930759   Curated Info